Jpn J Pharmacol 1992;58(Suppl):342 12 Kario K, Sato Y, Shiraya

Jpn J Pharmacol. 1992;58(Suppl):342. 12. Kario K, Sato Y, Shirayama M, et al. Inhibitory effects of azelnidipine (Calblock®) tablet on early-morning hypertension (At-HOME Study) [in Japanese]. J Clin Ther Med. 2008;24(12):1083–98. 13. Ishikawa J, Kario K, Hoshide S, et al. Determinants of exaggerated difference in morning and evening blood HSP inhibitor pressure measured by self-measured blood pressure monitoring in medicated hypertensive patients: Jichi Morning Hypertension Research (J-MORE) Study. Am J Hypertens. 2005;18(7):958–65.PubMedCrossRef 14. Fukunaga E, Ohkubo T, Ohara T, et al. Current situation in home blood pressure measurement in Japan: practice and

significance of 1,928 doctors. An investigation of the current situation in home blood Thiazovivin solubility dmso pressure measurement ARRY-438162 supplier [in Japanese]. J Blood Pressure. 2006;13:122–8. 15. Ohara T, Ohkubo T, Kikuya M, et al. Current situation in

home blood pressure measurement in Japan: practice and significance in 8,506 outpatients [in Japanese]. An investigation of the current situation in home blood pressure measurement. J Blood Pressure. 2006;13:103–10. 16. Matsui Y, Eguchi K, Shibasake S, et al. Association between the morning–evening difference in home blood pressure and cardiac damage in untreated hypertensive patients. J Hypertens. 2009;27:712–20.PubMedCrossRef 17. Sada T, Mizuno M, Miyama T, et al. Pharmacological characteristics of azelnidipine, a long-acting calcium antagonist,

having vascular affinity (No. 2)—antihypertensive effect and pharmacokinetics in spontaneously hypertensive rats (SHR) [in Japanese]. Jpn Pharmacol Ther. 2002;30(9):711–20. 18. Sada T, Mizuno M, Oohata K, et al. Antiatherosclerotic effect of azelnidipine, a long-acting calcium antagonist with high lipophilicity, in cholesterol-fed rabbits [in Japanese]. Jpn Pharmacol Ther. 2002;30(9):721–8.”
“Human papillomavirus (HPV) infection has a well established association with the development of genital warts and many types of cancer, including cervical, anal, oropharyngeal, and penile cancer.[2,3] It is the most common sexually transmitted infection in the US,[2] with an annual prevalence of 1% of the sexually BCKDHB active population.[3] It has been estimated that 80% of sexually active women will acquire HPV infection by the time they are aged 50 years.[2] Rates among men are also high, with estimates of ≈65–70% of males being infected with HPV.[4] Young people appear to be most at risk, with 74% of annual HPV infections occurring in men and women aged 14–24 years.[2] While most HPV infections are transient,[2,3] ≈10% lead to persistent infection.[2] Approximately 40 of the >100 known HPV types have been shown to infect the anogenital tract.

Comments are closed.